&nbsp;

Jan 2025

Drug

bevacizumab

Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™

Quick Link(s):

Nov 2024

Drug

bortezomib

Other Name(s): Velcade®

Quick Link(s):

Nov 2024

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Mar 2025

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Dec 1969

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Updated

Sep 2025

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Oct 2024

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

, Collapse Show fewer tags

Drugs Used:

bortezomib,

dexamethasone

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer